CG
OPRX icon

Cutler Group’s OptimizeRx OPRX Stock Holding History

Cutler Group’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,100
Closed -$23K – 5856
2021
Q3 		$23K Sell
1,100
-200
-15% -$12.5K ﹤0.01% 3231
2021
Q2 		$16K Buy
1,300
+100
+8% +$5.09K ﹤0.01% 3500
2021
Q1 		$5K Buy
+1,200
New +$57.9K ﹤0.01% 4373

Other funds holding OPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
GIPM
G2 Investment Partners Management New York $549M AUM 179.59% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return

Cutler Group's OPRX Position: Q1 2022 in Review

Cutler Group sold out of OptimizeRx (OPRX) in Q1 2022, closing a stake of 22 shares — an estimated $974 sold.

Cutler Group first reported a position in OPRX in Q1 2021 and held it in 3 quarters. The position peaked at $100K in Q1 2021. 153 funds tracked by Wall St. Rank hold OPRX as of Q1 2022.

  • Cutler Group reported no remaining OptimizeRx position as of Q1 2022 after selling out during the quarter.
  • Cutler Group sold 22 OptimizeRx shares in Q1 2022, an estimated $974.
  • Cutler Group first reported a position in OptimizeRx in Q1 2021 and held it in 3 quarters.
  • Cutler Group's OptimizeRx position peaked at $100K in Q1 2021.
  • 153 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2022.

Based on Cutler Group's 13F filing for Q1 2022, filed 14 Apr 2022.